Clin Nephrol. 2021 Jan;95(1):37-44. doi: 10.5414/CN110158.
Backgroundː Chronic kidney disease stage G5 (CKD G5) patients show an activated but impaired immune system. One function of the FOXP3 regulatory T (Treg) cells is to preserve tolerance to self while maintaining the ability to fight infectious agents. The aim of this pilot study is to evaluate longitudinal changes in Treg cells before and 1 month after the first dialysis treatment. Materials and methodsː CKD G5 patients not yet on dialysis were enrolled and started on hemodialysis (HD) or peritoneal dialysis (PD). Tregs were analyzed by flow cytometry at two time points: T0 (before the first dialysis treatment) and T1 (1 month after the first dialysis session). Wilcoxon test for dependent samples was used to compare the mean percentage difference between T0 and T1: Δ% = 100 × [(T1 - T0) / T0]. Resultsː 21 patients were enrolled: 8 on HD and 13 on PD. The proportion of total lymphocytes (low side scatter lymphocyte gate) and T lymphocytes (in the CD3CD4 gate) did not change significantly 1 month after the start of dialysis in both groups. Treg cells (as CD25FOXP3, FOXP3, or CD25CD127), analyzed as percentage of the lymphocyte gate, showed a significant increase post PD (CD25FOXP3: median = 35.92; p = 0.0425; FOXP3: median = 30.85; p = 0.0479 and CD25CD127: median = 23.71; p = 0.0215). The same populations, did not change 1 month after the first dialysis session. Conclusionː Our study is the first to evaluate longitudinal effects of dialysis on Treg cells in uremia and suggests that PD was more effective in increasing Treg levels 1 month post initiation of dialysis and may contribute to improvement of inflammatory status. Thus, PD may contribute to better outcomes for patients with renal dysfunction, also maintaining homeostasis of peritoneal and renal tissues.
慢性肾脏病 5 期(CKD G5)患者表现出激活但受损的免疫系统。FOXP3 调节性 T(Treg)细胞的一个功能是在保持对自身的耐受性的同时保持对感染因子的抵抗力。本初步研究旨在评估首次透析治疗前后 Treg 细胞的纵向变化。
未接受透析的 CKD G5 患者被招募并开始接受血液透析(HD)或腹膜透析(PD)。在两个时间点通过流式细胞术分析 Treg 细胞:T0(在首次透析治疗前)和 T1(首次透析后 1 个月)。采用配对样本 Wilcoxon 检验比较 T0 和 T1 之间的平均百分比差异:Δ%=100×[(T1-T0)/T0]。
共纳入 21 例患者:8 例接受 HD,13 例接受 PD。两组患者透析开始后 1 个月,总淋巴细胞(低侧散射淋巴细胞门)和 T 淋巴细胞(在 CD3CD4 门内)的比例均无显著变化。Treg 细胞(作为 CD25FOXP3、FOXP3 或 CD25CD127),作为淋巴细胞门的百分比分析,PD 后显著增加(CD25FOXP3:中位数=35.92;p=0.0425;FOXP3:中位数=30.85;p=0.0479 和 CD25CD127:中位数=23.71;p=0.0215)。同一群体在首次透析后 1 个月未发生变化。
本研究首次评估了透析对尿毒症患者 Treg 细胞的纵向影响,表明 PD 在开始透析后 1 个月内更有效地增加 Treg 水平,并可能有助于改善炎症状态。因此,PD 可能有助于改善肾功能障碍患者的预后,同时维持腹膜和肾脏组织的内稳态。